[
  {
    "question": "A 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/\u03bcL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?",
    "answer": "The most likely diagnosis is Primary CNS Lymphoma (PCNSL).\n\nThe key findings supporting this diagnosis are:\n1. Low CD4 count (<100 cells/\u03bcL)\n2. Positive EBV DNA in CSF (strongly associated with PCNSL in HIV patients)\n3. MRI showing solitary ring-enhancing lesion in corpus callosum\n4. Subacute neurological symptoms (headaches, confusion, ataxia)\n\nPCNSL is an AIDS-defining illness that typically occurs in severely immunocompromised patients. The presence of EBV DNA in CSF is highly sensitive and specific for PCNSL in this clinical context. The MRI findings are also characteristic, with PCNSL typically showing solitary or few lesions with weak ring enhancement, often involving deep brain structures like the corpus callosum.",
    "true_answer": "The most likely diagnosis for a patient with HIV, presenting with neurological symptoms and a solitary ring-enhancing lesion, is primary cerebral lymphoma."
  },
  {
    "question": "A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?",
    "answer": "Enfuvirtide (T-20, brand name Fuzeon) is the medication that acts on the gp41 subunit of the HIV envelope glycoprotein. It is a fusion inhibitor that prevents HIV from entering CD4+ T cells by binding to the gp41 subunit and blocking the conformational changes required for viral fusion with the cell membrane. However, it's important to note that enfuvirtide is not typically used as first-line therapy due to its need for twice-daily subcutaneous injections and is usually reserved for treatment-experienced patients with limited options.",
    "true_answer": "The medication that targets the gp41 subunit of the HIV envelope glycoprotein is enfuvirtide."
  },
  {
    "question": "A mother with HIV has given birth to a healthy boy 2 days ago. She takes her antiretroviral medication regularly and is compliant with the therapy. Before being discharged, her doctor explains that she cannot breastfeed the child since there is a risk of infection through breastfeeding and stresses that the child can benefit from formula feeding. The physician stresses the importance of not overheating the formula since Vitamin C may be inactivated by overheating. What molecular process could be impaired if the mother boiled the formula longer than needed?",
    "answer": "I should point out that while it's correct that HIV-positive mothers should avoid breastfeeding in settings where safe formula feeding is available, the question contains incorrect information about vitamin C and formula preparation.\n\nThe main concern with overheating formula is not related to vitamin C inactivation. The primary issues with overheating formula are:\n\n1. Destruction of nutrients (including proteins and some vitamins)\n2. Loss of the formula's proper consistency\n3. Risk of burns to the infant if too hot\n\nThe correct formula preparation involves:\n- Using clean water at around 70\u00b0C (to kill potential bacteria)\n- Letting it cool to body temperature before feeding\n- Following manufacturer's instructions carefully\n\nIf you're specifically interested in vitamin C molecular processes, we should discuss that separately, but it's not particularly relevant to safe formula preparation for HIV-exposed infants.",
    "true_answer": "If the formula is boiled longer than needed, resulting in the inactivation of Vitamin C, then collagen synthesis could be impaired."
  },
  {
    "question": "A 35-year-old woman presents to a physician\u2019s office for a follow-up visit. She recently underwent a complete physical examination with routine laboratory tests. She also had a Pap smear and testing for sexually transmitted diseases. Since her divorce 2 years ago, she had sexual encounters with random men at bars or social events and frequently did not use any form of protection during sexual intercourse. She was shown to be positive for the human immunodeficiency virus (HIV). Combination anti-retroviral treatment is initiated including zidovudine, didanosine, and efavirenz. One week later, she is rushed to the hospital where she is diagnosed with acute pancreatitis. What precautions in her medication will be required after pancreatitis resolves with treatment?",
    "answer": "In this case, didanosine (ddI) will need to be discontinued permanently as it is known to cause pancreatitis. This is a potentially serious adverse effect of didanosine, and re-exposure could lead to recurrent, potentially life-threatening pancreatitis.\n\nThe antiretroviral regimen will need to be modified by:\n1. Removing didanosine\n2. Substituting it with another appropriate antiretroviral agent based on resistance testing and patient factors\n3. Ensuring the new regimen maintains three active agents\n\nIt's also important to note that current HIV treatment guidelines no longer recommend zidovudine/didanosine-based regimens as first-line therapy. A more modern regimen would likely be recommended going forward.",
    "true_answer": "After resolving pancreatitis, didanosine should be replaced with lamivudine to avoid recurrence."
  },
  {
    "question": "A physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?",
    "answer": "The gp120 surface glycoprotein would be the most likely target for antibody development.\n\nThis is because:\n1. gp120 is exposed on the viral surface\n2. It's critical for viral entry into CD4+ T cells\n3. It's highly antigenic and a major target of neutralizing antibodies\n4. It's one of the main envelope proteins recognized in diagnostic tests\n\nThe gp120 protein is particularly important as it binds to CD4 receptors, making it a logical target for neutralizing antibodies that could prevent viral entry into cells.",
    "true_answer": "The most likely target of the antibody being designed for HIV envelope proteins is gp120."
  },
  {
    "question": "A 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?",
    "answer": "The most likely causal organism is Aspergillus fumigatus. The clinical presentation (fever, hemoptysis), radiographic finding (fibrocavitary lesion), and most importantly, the microscopic finding of septate hyphae branching at acute angles (approximately 45 degrees) are classic features of invasive pulmonary aspergillosis. This opportunistic infection is more common in immunocompromised patients, including those with advanced HIV disease.",
    "true_answer": "The most likely causal organism for the symptoms presented is Aspergillus fumigatus."
  },
  {
    "question": "A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3\u20134 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?",
    "answer": "The greatest risk when adding valganciclovir to this patient's current regimen is bone marrow suppression (particularly neutropenia and anemia). This risk is especially significant because the patient is already taking zidovudine (AZT), which is also known to cause bone marrow suppression.\n\nThe combination of these two medications (valganciclovir and zidovudine) can have an additive myelosuppressive effect, potentially leading to:\n- Severe anemia\n- Neutropenia\n- Thrombocytopenia\n\nThis patient will need close monitoring of their complete blood count (CBC) while on this combination of medications. If severe cytopenias develop, dose adjustments or medication changes may be necessary.",
    "true_answer": "Treatment with valganciclovir places the patient at increased risk for pancytopenia."
  },
  {
    "question": "A 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient\u2019s concern?",
    "answer": "For an infant born to an HIV-positive mother, HIV DNA PCR testing is the most appropriate diagnostic test. This test should be performed at 14-21 days of life, 1-2 months, and 4-6 months of age.\n\nHIV antibody testing is not useful in newborns because maternal antibodies cross the placenta and can persist in the infant for up to 18 months, potentially giving false-positive results. The DNA PCR test directly detects viral genetic material, making it a more reliable method for early diagnosis of HIV infection in infants.\n\nIn the meantime, the mother should start antiretroviral therapy immediately to reduce the risk of mother-to-child transmission.",
    "true_answer": "The most appropriate test for early HIV diagnosis in a newborn is the polymerase chain reaction (PCR) for HIV RNA."
  },
  {
    "question": "A 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?",
    "answer": "In this scenario, the most appropriate next steps are:\n\n1. Counsel the patient about his legal and ethical obligation to inform sexual partners who may have been exposed to HIV\n\n2. Strongly encourage the patient to disclose his HIV status to his wife himself, offering support and assistance with the disclosure process\n\n3. Inform the patient that if he refuses to notify his wife, the physician may have a legal and ethical duty to warn her due to her being at risk (many states have specific laws about partner notification for HIV)\n\n4. Document all discussions and decisions carefully\n\nThe physician should not immediately break confidentiality, but should work with the patient to achieve voluntary disclosure while making it clear that partner notification may be required by law. The exact requirements vary by state/jurisdiction, but the protection of public health generally allows for partner notification in cases where there is a clear risk of HIV transmission to an identifiable person.",
    "true_answer": "The physician should report the HIV infection to the national health authorities while maintaining confidentiality per regulations."
  },
  {
    "question": "A 41-year-old HIV-positive male presents to the ER with a 4-day history of headaches and nuchal rigidity. A lumbar puncture shows an increase in CSF protein and a decrease in CSF glucose. When stained with India ink, light microscopy of the patient\u2019s CSF reveals encapsulated yeast with narrow-based buds. Assuming a single pathogenic organism is responsible for this patient\u2019s symptoms, what diagnostic test results would also be expected in this patient?",
    "answer": "Based on the description (India ink showing encapsulated yeast with narrow-based buds in CSF), this patient likely has Cryptococcal meningitis, a common opportunistic infection in HIV-positive individuals.\n\nExpected additional diagnostic test results would include:\n\n1. Positive cryptococcal antigen (CrAg) test in both CSF and serum\n2. Positive CSF culture for Cryptococcus neoformans\n3. Low CD4 count (typically <100 cells/\u03bcL)\n4. Elevated intracranial pressure on initial lumbar puncture\n5. Positive serum CrAg (usually precedes CSF positivity)\n\nThe most important of these would be the cryptococcal antigen test, which has high sensitivity and specificity for confirming the diagnosis.",
    "true_answer": "A latex agglutination test specific for Cryptococcal meningitis would also be expected in this patient."
  },
  {
    "question": " What would be the best methodological approach to study microRNAs as therapeutic targets in HIV patients?",
    "answer": "For studying microRNAs as therapeutic targets in HIV patients, I would recommend this stepwise approach:\n\n1. Initial screening:\n- Use RNA sequencing to identify differentially expressed microRNAs in HIV+ vs. healthy controls\n- Focus on miRNAs known to interact with HIV replication cycle\n\n2. Validation studies:\n- qRT-PCR validation of candidate miRNAs\n- Analysis in different patient cohorts (treatment-naive, on ART)\n\n3. Functional studies:\n- In vitro studies using primary CD4+ T cells and macrophages\n- miRNA inhibition/overexpression experiments\n- Assessment of HIV replication and cellular responses\n\n4. Safety assessment:\n- Evaluate off-target effects\n- Study impact on immune function\n- Consider delivery methods for potential therapeutic applications\n\nThis should provide systematic evidence for miRNA therapeutic potential. However, I recommend consulting with a molecular biology specialist for detailed protocol design.",
    "true_answer": "To study microRNAs as therapeutic targets in HIV patients, the best methodological approach would likely include a combination of in vitro experiments, in vivo animal models, and clinical trials . Initial in vitro experiments would involve the use of HIV-infected cell lines or primary cells to study the function and expression of specific microRNAs in relation to HIV replication and pathogenesis . This research would provide insights into the potential roles of microRNAs in HIV infection and help identify candidate microRNAs for therapeutic targeting . Next, in vivo animal models, such as humanized mice, should be employed to study the effects of modulating specific microRNAs on HIV infection and disease progression . These models would help evaluate the safety and efficacy of potential microRNA-based therapies, as well as investigate the potential for off-target effects and immunogenicity . Techniques such as delivery of microRNA mimics or antagomirs, viral vector-mediated overexpression or knockdown, and CRISPR-Cas9 editing can be used to manipulate microRNA expression in these models  . Finally, clinical trials should be conducted to validate the safety, efficacy, and tolerability of potential microRNA-based therapies in HIV patients . These trials would involve the enrollment of HIV-positive patients to receive the experimental treatment(s) under controlled conditions, with rigorous monitoring of viral load, treatment-related adverse events, immune function, and other relevant parameters . The results of these clinical trials would be instrumental in determining the clinical feasibility of microRNA-based therapies for treating HIV infections ."
  },
  {
    "question": "What is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?",
    "answer": "DNA methylation changes have been observed in HIV infection, though our understanding is still evolving. In latent HIV-1, hypermethylation of the viral promoter region (5' LTR) is associated with viral silencing and maintenance of latency. During active infection, global DNA methylation patterns in host cells are altered, with studies showing both hyper- and hypomethylation at various genomic locations. However, many details about specific methylation profiles and their functional consequences remain under investigation, and more research is needed for a complete understanding of these epigenetic changes.",
    "true_answer": "I searched for your question and found some relevant results. According to these results, **DNA methylation** is a possible mechanism that regulates the **latency** and **reactivation** of **HIV-1 provirus** in infected cells  . However, the **methylation profiles** of HIV-1 proviral DNA may vary depending on the **disease progression**, **antiretroviral therapy**, and **cell type** of the patients ."
  }
]